China / Hong Kong Industry Focus

China Insurance Sector

Refer to important disclosures at the end of this report

DBS Group Research . Equity

25 Jan 2024

How much of the negatives are priced in?

- Our stress test suggests another 14%-30% downside risk, negatives should have priced in
- The stress test on a conservative basis with 5%-50% impairment across asset classes and additional 0.8x justified P/B applied to the post-impairment fair value
- Three potential events may signal positive investment sentiment and beef up share prices
- Suggest investors gradually accumulate shares upon share price pullback. We like <u>Ping An</u> (2318 HK) for its leading market position

Our stress test indicates a 14%-30% downside amid economic slowdown in China. We assume insurers property exposure would be impaired by 5%-50% across estimated asset classes vis-à-vis property risk under a destressed scenario, where China property sector may suffer extended downturn, there would be a 24%-28% trimming of insurers' book value. Additionally, we applied a 0.8x P/B to the post-impairment fair value to reflect an overall economic slowdown in China. As a result, our stress test indicates a 14%-30% downside to insurers' current market capitalization, we believe negatives should have already much priced in.

Three potential catalysts may lead to positive sentiment. The deteriorating property sector has eroded household wealth and consumption, leading to negative feedback for the macroeconomy in China, as many investors are left worried. We believe any of three potential events may signal positive investment sentiment and beef up share prices. These include 1) the 3rd Plenary Meeting of the 20th Central Committee; 2) effective policy stimulus to bolster the slumping property market, and 3) the end of another offshore bond repayment peak cycle for developers, which will likely be seen by end-1H24.

Suggest investors gradually accumulate shares upon pullback. With the risk-reward looking increasingly attractive and the current share prices already pricing in much of the negatives based on our stress test, we suggest investors gradually accumulate shares upon share price pullbacks. Among China insurers, we continue to like Ping An (2318 HK) for its leading market position and undemanding valuation.

HSI: 16,212

ANALYSTS

Ken Shih +852 36684184 kenshih@dbs.com Iris GAO +852 36684196 irisgao@dbs.com

Recommendation & valuation

Insurance company	Ticker	Rating	Target Price	Potential Return	
China Life - H	2628 HK	BUY	16.00	70.9%	
<u>CPIC - H</u>	2601 HK	BUY	24.00	58.9%	
<u>Ping An Ins - H</u>	2318 HK	BUY	66.00	90.7%	

Source: Bloomberg Finance L.P., DBS Bank (Hong Kong) Limited ("DBS HK")

Closing price as of 25 Jan 2024

China Insurance Sector



How much of the negatives are priced in?

China insurers' share prices have retreated 38%, on average, since the end of July 2023, with concerns over insurers' exposure to the China property sector playing a central role. Despite regulators rolling out plenty of policy stimuli to stabilise the property sector, these measures haven't been deemed firm and effective enough to stabilise the market. The housing prices have dropped consecutive 7 months since then, and in 2H23, developers experienced significant losses due to asset impairment and declining profit margins. At the same time, concerns about local government financial vehicle (LGFV) debt and the potential default of mortgage and developer loans issued by banks have also accelerated the sell-off by investors, serving as a side effect of the turmoil in the property sector.

To address the frequently asked questions regarding how much insurers' share prices have factored in the worst-case scenario concerning their exposure to the property sector, we conducted a stress test to analyse the potential impairment of China insurers' property investment exposure. We assessed insurers' fair value after the impairment and discussed the potential catalysts needed to revisit China life insurers.

Our analysis encompasses a thorough examination of insurers' exposure to the property sector, including 1) bonds and debt, non-standard assets, equities, and commercial buildings, which are exposed to the property sector, and LGFV debt within the insurance investment portfolio; 2) mortgages, developer loans, and LGFV, and debt, trust, and asset management schemes relating to the property sector within the banking arm, as well as assets within the real estate subsidiaries. We also made impairment assumptions based on the asset class. Under an extreme, distressed scenario, we assume 1) debt, equities, NSAs would be impaired by 50%; 2) mortgage and developer loans would be impaired by 5% and 30%, respectively; 3) estimated LGFV exposure would be impaired by 5%; and 4) assets within the "real estate subsidiaries" would be impaired by 50%, except for investment properties, which would be impaired by 25%. It's important to note that our assumptions are based on an extreme, distressed scenario, when the housing price decline reaccelerates and property risk spills over to the broader financial system, possibly causing systemic risks, which we currently consider to be only a remote possibility.

Fig 1. Asset class and impairment assumptions

Major subsidiaries and asset class	Impairment assumption
Insurance funds	· ·
Exposure to property sector	
Bonds and debts	50%
Non-standard assets	50%
Equities	50%
Commercial buildings	30%
Exposure to LGFV debts	5%
Bank	
Loans to property sector	
Mortgage	5%
Developer loans	30%
Financial investment	
Government bonds	5%
Debt, trust and asset management so	heme 50%
Major real estate subsidiary	
Short-term debt receivables	50%
Equity investments (Projects)	50%
Long-term debt investments and receive	ables 50%
Receivables	50%
Investment properties	25%
Financial investments	50%

Source: DBS HK

Taking Ping An as an example, our analysis suggests that potentially Rmb225bn of Ping An's property exposure is at risk, accounting for 24% of its shareholder equity. The book value is expected to reduce from Rmb918bn by end-1H23 to Rmb694bn, which we consider to be Ping An's fair value under distressed scenario. We further apply a 0.8x P/B ratio to Ping An's post-impairment fair value to reflect an extended downturn in the property sector and an overall economic slowdown in China. The justified P/B ratio of 0.8x is derived from an average return on equity (ROE) of 11% for China insurers, a cost of equity of 13.4%, and a growth rate of 3%. We hence estimate Ping An's fair value to be Rmb555b, indicating a further 14% downside compared to the current market capitalization adjusted for H-share value (Figure 2).

We apply the same methodology to China Life's and CPIC's implied post-impairment values and estimating the downside based on their market capitalisation adjusted for H-share value. We hence estimate that China Life and CPIC may have further downsides of 30% and 20%, respectively (Figures 3 & 4).

China Insurance Sector



We also conduct a sensitivitiy analysis on the P/B ratio applied to insurers' post-impairment fair value. We believe that a 0.7x P/B ratio suggests an extreme, distressed scenario, wherein systemic risk arises in China, prompting regulatory intervene – a situation we consider highly unlikely to materialize. In such a scenario, China life insurers' share prices may further decline by 25%-38% compared to their current prices.

Insurers' share prices have also been depressed due to the recent rumour that the regulator requires Ping An to take over distressed developer Country Garden (2007 HK). Ping An Group immediately denied the rumour and announced it had sold all of its shareholdings in Country Garden by 3Q23. We think investors are overly concerned about the potential implications, as it is highly unlikely that Ping An would directly take over the developer. Regulators have strict guidelines to regulate insurance fund investments, including limitations on the value of a single real estate asset not exceeding 5% of the company's total assets and a red line prohibiting insurance funds from directly investing in property development and the sale of commercial residential properties. Therefore, we believe insurers have minimal incentives to take over developers, and their internal risk management principles won't allow them to be involved with names that were already subject to default events. As the majority of POE developers are already in default, and insurers have already made credit charges in advance for another repayment cycle for developers in 1H24, we don't expect the credit charges to be a major concern for China life insurers' earnings in 2024.

Despite the gloomy investment outlook, we see the following potential events providing positive signals to the market, which will help drive an improvement in investment sentiment, in our view. These potential events include 1) the confirmed announcement of the 3rd Plenary Meeting of the 20th Central Committee to outline how Chinese leadership plans to manage the structural slowdown and boost domestic consumption; 2) effective policy stimulus to be rolled out to bolster the property market; and 3) the end of another offshore bond repayment peak cycle for developers, which will likely be seen by 1H24.

We maintain our BUY ratings on Ping An, China Life and CPIC with TP at HK\$66, HK\$16 and HK\$24, respectively, indicating 70%-100% upside. With the risk-reward looking increasingly attractive and the current share prices already pricing in much of the negatives based on our stress test (Figure 4), we suggest investors gradually accumulate shares upon a share price pullback. Among China insurers, we continue to like Ping An (2318 HK) for its leading market positioning and undemanding valuation.

Fig 4. Stress test sensitivity

Insurers/PB ratio	0.6x	0.7x	0.8x	0.9x	1.0x
Ping An	-36%	-25%	-14%	-4%	+7%
China Life	-47%	-38%	-30%	-21%	-12%
CPIC	-40%	-30%	-20%	-10%	+0%



Fig 2. Ping An's real estate exposure and implied fair value post-impairment

		Total amount		Impairment amoun
Major subsidiaries	% owned	(Rmb bn)	% impaired	(Rmb br
Ping An insurance funds	100%			
Bonds and debts		39.2	50%	19.
Equities		11.9	50%	6.
China Fortune Land		2.2	50%	1.
China Jinmao		6.8	50%	3.
Country Garden*		2.7	50%	1.
Other equities		0.2	50%	0.
Commerical building **		158.3	30%	47.
Raffles Cityplazas		30.0	3096	9
Ping An HK Building		10.1	30%	3.
Beijing Lize CBD		18.8	30%	5.
SITC, Shanghai		6.1	30%	1.
Lloyd's Building London		0.9	30%	0.
Shanghai Yibin		13.3	30%	4.
Vivid Synergy		10.4	30%	3.
Hangzhou Pingjiang Investment		1.4	30%	0.
Shenzhen Anpu Development		5.6	30%	1.
Other		61.6	30%	18.
LGFV - based on DBS estimate		230.1	5%	11.
Total (Insurance funds)		439.5		84.
Ping An Bank	58%			
Loan				
Mortgage		841.6	596	42.
Developer		275.9	30%	82
Sub-total		1,117.6	1196	124.
(-) Estimated reserve buffer				50
Adjusted sub-total				74.
Financial asset investments				
Government bonds		689.9	596	34
Debt, trust and asset management scheme		99.4	50%	49
Sub-total		789.3		84.
Total (Ping An Bank)		1,906.8		159.
Major subsidiaries - Ping An Real Est	100%	.,		
Short-term debt receivables		41.8	50%	20.
Equity investments (Projects)		34.6	5096	17.
Long-term debt investments and receivables		11.9	5096	5.
Receivables		6.9	5096	3
Investment properties		1.9	2596	0.
Financial investments		0.3	50%	0.
Total (PARE)		97.3	3070	48.
Grand-total		27.5		224.
di and-total				224.
Ping An Group's 1H23 equity attributable to shareholders				918.
Estimated book value after impairment				693.6
Adi. P/B ratio		0.6x	0.7x	3.0
Implied post-impairment value of Ping An Group		416.2	485.5	554.
Market cap. as of 23 Jan (Rmb bn)		710.2	-55.5	647.
Implied downside risk to current share price		-35.7%	-25.0%	-14.29



Fig 3. China Life's real estate exposure and implied fair value post-impairment

		Total amount		mpairment amount
Major subsidiaires	% owned	(Rmb bn)	% impaired	(Rmb bn)
China Life insurance fund	100%			
Bonds and debts		10.8	50%	5.4
Non-standardized asset		32.3	50%	16.2
Equities		21.5	50%	10.8
Commercial building		161.6	30%	48.5
LGFV - based on DBS estimate		177.8	596	8.9
Total (Insurance funds)		404.0		89.7
China Guangfa Bank	44%			
Loan				
Mortgage		284.8	596	14.2
Devloper		116.2	30%	34.9
Sub-total		401.0		49.1
(-) Estimated reserve buffer				8.8
Adjusted impair amount				40.3
Financial asset investments				
Government bonds		413.9	5%	20.7
Other debt scheme		77.6	50%	38.8
Sub-total		491.6		59.5
Total (China Guangfa Bank)		892.58		99.8
Grand-total Grand-total				133.3
China Life's 1H23 equity attribute to shareholders				477.9
Estimated book value after impairment				344.6
Adj. P/B ratio		0.6x	0.7x	0.8x
Implied post-impairment value of Ping An Group		206.8	241.2	275.7
Market cap. as of Jan 17 (Rmb bn) adjusted for H-share value	e			392.2
Implied downside risk to current share price		-47.3%	-38.5%	-29.7%



Fig 4. CPIC's real estate exposure and implied fair value post-impairment

		Total amount	I	mpairment amount
Major subsidiaires	% owned	(Rmb bn)	% impaired	(Rmb bn)
CPIC insurance funds	98%			
Bonds and debts		1.5	50%	0.7
Non-standardized asset		64.2	50%	32.1
Equities		25.4	50%	12.7
Commercial building		12.7	30%	3.8
Shanghai (Chongming) Project		0.9	30%	0.3
Xinbaoyu		3.6	30%	1.1
LGFV - based on DBS estimate		166.0	596	8.3
Sub-total (Insurance funds)		269.8		57.7
Shanghai Rural Commercial Bank (SR	6%			
Loan				
Mortgage		113.3	596	5.7
Devioper		100.5	30%	30.1
Sub-total		213.8		35.8
(-) Estimated reserve buffer				18.7
Adjusted impair amount				17.1
Financial asset investments				
Government bonds		120.0	596	6.0
Other debt scheme		2.3	5096	1.1
Sub-total		122.3		7.1
Total (SRCB)		336.06		24.2
Grand-total				59.1
CPIC's 1H23 equity attribute to shareholders				243.0
Estimated book value after impairment				183.9
Adj. P/B ratio		0.6x	0.7x	0.8x
Implied post-impairment value of CPIC		110.4	128.7	147.1
Market cap. as of Jan 17 (Rmb bn) adjusted for H-share valu	ie			184.4
Implied downside risk to current share price		-40.2%	-30.2%	-20.2%



Fig 5. Peers' comparison table

		Price	DBS	TP	Mkt Cap	PBV (x)		PEV* (x)		Div Yield	1 (%)	ROE (%)
Coverage	Ticker	(LC)	rating	(HK\$)	(US\$ m)	FY24F	FY25F	FY24F	FY25F	FY24F	FY25F	FY24F	FY25F
H-share insure	rs												
AIA	1299 HK	65.05	BUY	118.00	88,954	1.9	1.8	1.3	1.2	2.796	2.996	13.596	13.8%
China Life - H	2628 HK	9.36	BUY	16.00	82,519	0.6	0.5	0.2	0.1	7.296	7.9%	12.6%	13.196
CPIC - H	2601 HK	15.10	BUY	24.00	25,529	0.5	0.5	0.3	0.3	8.596	9.6%	13.796	14.096
Manulife	945 HK	168.00	BUY	182.00	38,724	1.0	1.0	0.8	0.7	5.4%	5.096	11.596	12.196
PICC Group - H	1339 HK	2.54	HOLD	2.80	25,702	0.4	0.3	0.3	0.3	10.996	12.096	8.896	8.9%
PICC P&C	2328 HK	9.95	BUY	12.50	26,953	0.8	0.7	n.a.	n.a.	6.296	7.096	12.496	12.8%
Ping An Ins - H	2318 HK	34.60	BUY	66.00	88.863	0.5	0.5	0.5	0.5	9.196	9.9%	13.6%	13.896
China Taiping	966 HK	6.72	BUY	9.50	2.779	0.2	0.2	0.1	0.1	8.296	9.6%	6.2%	6.3%
ZhongAn	6060 HK	13.96	BUY	27.00	2.446	1.0	1.0	n.a.	n.a.	0.096	0.096	1.896	2.996
Prudential	2378 HK	82.50	BUY	130.00	28.293	1.4	1.3	0.6	0.6	2.196	2.396	13.196	13.096
Average	25701110	02.50	501	150.00	20,230	0.8	0.8	0.5	0.5	6.0%	6.6%	10.7%	11.0%
•						0.0	0.0	0.0	0.0	0.070	0.070	10.770	11.070
A-share insure													
China Life - A	601628 CH	28.69	HOLD	27.68	82,520	2.1	2.0	0.6	0.5	2.096	2.296	12.696	13.196
CPIC - A	601601 CH	24.77	HOLD	24.62	25,530	1.0	0.9	0.5	0.5	4.596	5.096	13.796	14.096
Ping An Ins - A	601318 CH	41.15	BUY	52.74	88,864	0.7	0.7	0.7	0.6	6.6%	7.2%	11.596	12.196
PICC Group - A	601319 CH	5.10	HOLD	5.51	25,703	0.9	0.8	1.6	1.5	4.7%	5.2%	8.8%	8.9%
Average						1.2	1.1	0.9	8.0	4.5%	4.9%	11.7%	12.0%
Regional Insure	ers												
Sun Life Financial	SLF CN	69.17	NR	NA	29,727	1.8	1.6	n.a.	n.a.	4.696	4.8%	17.6%	17.3%
Great-West Lifect	o GWO CN	43.84	NR	NA	30,133	1.7	1.5	n.a.	n.a.	4.996	5.196	16.396	16.5%
AXA	CS FP	30.71	BUY	35.00	75,451	1.4	1.3	2.3	2.0	6.596	7.096	17.096	16.6%
Allianz SE	ALV GY	247.50	BUY	286.00	104,356	1.6	1.5	2.0	1.9	5.3%	5.6%	16.8%	16.6%
Legal & General (GD LGEN LN	2.52	NR	NA	18,993	2.5	2.3	n.a.	n.a.	8.496	9.0%	28.7%	29.2%
Aviva PLC	AV/ LN	4.34	NR	-NA	15.066	1.2	1.2	n.a.	n.a.	8.196	8.6%	12.796	11.8%
Average						1.7	1.6	2.1	2.0	6.3%	6.7%	18.2%	18.0%
apan & Korea													
- 1	032830 KS	63.800	NR	NA	9.257	0.3	0.2	0.2	0.2	6.4%	6.9%	4.8%	4.996
Samsung Life	032830 KS 088350 KS	2.690	NR NR	NA NA		0.3				7.3%			
Hanwha Life		-,			1,728		0.2	n.a.	n.a.		8.4%	4.6%	4.8%
Tongyang Life	082640 KS	4,470	NR	NA	536	0.2	0.2	n.a.	n.a.	9.8%	10.096	5.6%	6.3%
Japan Post Insura	•	2,172	NR -	· · · · · · · · · NA	6,942	0.3	0.3	n.a.	n.a.	4.3%	4.496	3.5%	3.296
Dai-ichi Life Holdi	ng 8750 JP	2,361	NR	NA	21,102	0.7	0.6	0.3	0.2	3.7%	3.8%	9.096	8.8%
Average						0.3	0.3	0.2	0.2	6.3%	6.7%	5.5%	5.6%
Other Asian in:													
Cathay FHC	2882 TT	44.35	NR	NA	20,656	0.9	0.8	n.a.	n.a.	3.5%	3.8%	10.296	10.296
Fubon FHC Shin Kong FHC	2881 TT 2888 TT	64.60 8.57	NR NR	NA NA	26,495 4,199	1.1 n.a.	1.0 n.a.	n.a. n.a.	n.a. n.a.	3.496 1.896	3.796 2.396	11.296 n.a.	11.196 n.a.
Bangkok Life	BLA TB	19.10	NR NR	NA NA	922	0.7	0.6	n.a.	n.a.	4.196	4.796	8.8%	9.5%
BAO Viet Holding		40.700	NR	NA	1.232	1.3	1.3	n.a.	n.a.	2.3%	2.5%	8.096	8.896
ICICI Prudential L		485.25	NR	NA	8.302	6.4	6.1	1.5	1.3	0.496	0.496	11.5%	12.796
Tokio Marine	8766 JP	3820.00	HOLD	3,800.00	51,790	1.8	1.7	n.a.	n.a.	3.296	3.7%	14.896	13.796
Average					-	1.0	0.9	n.a.	n.a.	3.0%	3.4%	9.5%	9.9%

Note: BBG or Visible Alpha consensus used for non-rated (NR) stocks Closing price as of 25 Jan 2024





DBS HK recommendations are based on an Absolute Total Return* Rating system, defined as follows:

STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)

BUY (>15% total return over the next 12 months for small caps, >10% for large caps)

HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)

FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)

SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Completed Date: 25 Jan 2024 17:52:45 (HKT) Dissemination Date: 25 Jan 2024 19:01:52 (HKT)

Sources for all charts and tables are DBS HK unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank (Hong Kong) Limited ("DBS HK"). This report is solely intended for the clients of DBS Bank Ltd., DBS HK, DBS Vickers (Hong Kong) Limited ("DBSV HK"), and DBS Vickers Securities (Singapore) Pte Ltd. ("DBSVS"), its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS HK.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd., DBS HK, DBSV HK, DBSVS, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets. Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBS Vickers Securities (USA) Inc ("DBSVUSA"), a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

China Insurance Sector



ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

1. DBS Bank Ltd, DBS HK, DBSVS or their subsidiaries and/or other affiliates have proprietary positions in AlA Group Ltd (1299 HK), China Life Insurance Co Ltd (2628 HK), China Pacific Insurance Group Co Ltd (2601 HK), People's Insurance Co Group of China Ltd/The (1339 HK), PICC Property & Casualty Co Ltd (2328 HK), Ping An Insurance Group Co of China Ltd (2318 HK) and China Taiping Insurance Holdings Co Ltd (966 HK) recommended in this report as of 23 Jan 2024.

DBS Bank Ltd, DBS HK, DBSVS or their subsidiaries and/or other affiliates have a proprietary position in Tokio Marine Holdings Incorporated (8766 IP) recommended in this report as of 29 Dec 2023.

2. Compensation for investment banking services:

DBS Bank Ltd, DBS HK, DBSVS, their subsidiaries and/or other affiliates of DBSVUSA have received compensation, within the past 12 months for investment banking services from AlA Group Ltd (1299 HK) as of 31 Dec 2023.

DBS Bank Ltd, DBS HK, DBSVS, their subsidiaries and/or other affiliates of DBSVUSA, within the next 3 months, will receive or intend to seek compensation for investment banking services from Ping An Bank Co Ltd (000001 CH) as of 31 Dec 2023.

3. DBS Bank Ltd, DBS HK, DBSVS, their subsidiaries and/or other affiliates of DBSVUSA have managed or co-managed a public offering of securities for AIA Group Ltd (1299 HK) in the past 12 months, as of 31 Dec 2023.

DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Directorship:

David Hing-Yuen HO, a member of DBS Group Holdings Board of Directors, is a Director of Sun Life Financial Inc as of 31 Dec 2023.

5. Disclosure of previous investment recommendation produced:

DBS Bank Ltd, DBSVS, DBS HK, their subsidiaries and/or other affiliates of DBSVUSA may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed on page 1 of this report to view previous investment recommendations published by DBS Bank Ltd, DBS HK, DBSVS, their subsidiaries and/or other affiliates of DBSVUSA in the preceding 12 months.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.





RESTRICTIONS ON DISTRIBUTION

	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is being distributed in Australia by DBS Bank Ltd, DBSVS or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946.
	DBS Bank Ltd, DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS Bank Ltd and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws.
	Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.
Hong Kong	This report is being distributed in Hong Kong by DBS Bank Ltd, DBS Bank (Hong Kong) Limited and DBS Vickers (Hong Kong) Limited, all of which are registered with or licensed by the Hong Kong Securities and Futures Commission to carry out the regulated activity of advising on securities. DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore.
	For any query regarding the materials herein, please contact Dennis Lam (Reg No. AH 8290) at dbsvhk@dbs.com.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies.
	Wong Ming Tek, Executive Director, ADBSR
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6878 8888 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
	For any query regarding the materials herein, please contact [Chanpen Sirithanarattanakul] at [research@th.dbs.com]
United Kingdom	This report is produced by DBS HK which is regulated by the Hong Kong Monetary Authority
	This report is disseminated in the United Kingdom by DBS Bank Ltd, London Branch ("DBS UK"). DBS Bank Ltd is regulated by the Monetary Authority of Singapore. DBS UK is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request.
	In respect of the United Kingdom, this report is solely intended for the clients of DBS UK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS UK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity





following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.

Dubai International Financial Centre

This communication is provided to you as a Professional Client or Market Counterparty as defined in the DFSA Rulebook Conduct of Business Module (the "COB Module"), and should not be relied upon or acted on by any person which does not meet the criteria to be classified as a Professional Client or Market Counterparty under the DFSA rules.

This communication is from the branch of DBS Bank Ltd operating in the Dubai International Financial Centre (the "DIFC") under the trading name "DBS Bank Ltd. (DIFC Branch)" ("DBS DIFC"), registered with the DIFC Registrar of Companies under number 156 and having its registered office at units 608 - 610, 6th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates.

DBS DIFC is regulated by the Dubai Financial Services Authority (the "DFSA") with a DFSA reference number F000164. For more information on DBS DIFC and its affiliates, please see http://www.dbs.com/ae/our--network/default.page.

Where this communication contains a research report, this research report is prepared by the entity referred to therein, which may be DBS Bank Ltd or a third party, and is provided to you by DBS DIFC. The research report has not been reviewed or authorised by the DFSA. Such research report is distributed on the express understanding that, whilst the information contained within is believed to be reliable, the information has not been independently verified by DBS DIFC.

Unless otherwise indicated, this communication does not constitute an "Offer of Securities to the Public" as defined under Article 12 of the Markets Law (DIFC Law No.1 of 2012) or an "Offer of a Unit of a Fund" as defined under Article 19(2) of the Collective Investment Law (DIFC Law No.2 of 2010).

The DFSA has no responsibility for reviewing or verifying this communication or any associated documents in connection with this investment and it is not subject to any form of regulation or approval by the DFSA. Accordingly, the DFSA has not approved this communication or any other associated documents in connection with this investment nor taken any steps to verify the information set out in this communication or any associated documents, and has no responsibility for them. The DFSA has not assessed the suitability of any investments to which the communication relates and, in respect of any Islamic investments (or other investments identified to be Shari'a compliant), neither we nor the DFSA has determined whether they are Shari'a compliant in any way.

Any investments which this communication relates to may be illiquid and/or subject to restrictions on their resale. Prospective purchasers should conduct their own due diligence on any investments. If you do not understand the contents of this document you should consult an authorised financial adviser.

United States

This report was prepared by DBS HK. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.

Other jurisdictions

In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

DBS Bank (Hong Kong) Limited

13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong Tel: (852) 3668-4181, Fax: (852) 2521-1812

China Insurance Sector



DBS Regional Research Offices

HONG KONG DBS Bank (Hong Kong) Ltd Contact: Dennis Lam

13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong

Tel: 852 3668 4181 Fax: 852 2521 1812 e-mail: dbsvhk@dbs.com DBS Bank Ltd
Contact: Andy Sim
12 Marina Boulevard,
Marina Bay Financial Centre Tower 3
Singapore 018982
Tel: 65 6878 8888
e-mail: groupresearch@dbs.com
Company Regn. No. 196800306E

SINGAPORE

INDONESIA PT DBS Vickers Sekuritas (Indonesia) Contact: Maynard Priajaya Arif DBS Bank Tower Ciputra World 1, 32/F

Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel: 62 21 3003 4900 Fax: 6221 3003 4943

e-mail: indonesiaresearch@dbs.com

THAILAND DBS Vickers Securities (Thailand) Co Ltd Contact: Chanpen Sirithanarattanakul

989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Bangkok Thailand 10330 Tel. 66 2 857 7831 Fax: 66 2 658 1269

e-mail: research@th.dbs.com Company Regn. No 0105539127012

Securities and Exchange Commission, Thailand